<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00043147</url>
  </required_header>
  <id_info>
    <org_study_id>ENTERON-00-02</org_study_id>
    <secondary_id>MSKCC-01149</secondary_id>
    <secondary_id>CDR0000256305</secondary_id>
    <secondary_id>NCI-G02-2098</secondary_id>
    <secondary_id>RPCI-DS-01-09</secondary_id>
    <nct_id>NCT00043147</nct_id>
  </id_info>
  <brief_title>Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease</brief_title>
  <official_title>A Phase III, Randomized, Placebo-Controlled, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Oral Beclomethasone 17, 21-Dipropionate (BDP) in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Grade II Graft vs. Host Disease With Gastrointestinal Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Beclomethasone combined with prednisone may be an effective treatment for&#xD;
      graft-versus-host disease caused by stem cell transplantation. It is not yet known if&#xD;
      prednisone is more effective with or without beclomethasone in treating gastrointestinal&#xD;
      graft-versus-host disease.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to determine the effectiveness of prednisone with or&#xD;
      without beclomethasone in treating patients who have graft-versus-host disease afftecting the&#xD;
      gastrointestinal system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of beclomethasone dipropionate and prednisone vs placebo and&#xD;
           prednisone, in terms of time to treatment failure, in patients with grade II&#xD;
           graft-vs-host disease with gastrointestinal symptoms.&#xD;
&#xD;
        -  Compare the proportion of treatment failures on study days 10, 30, 50, 60, and 80 in&#xD;
           patients treated with these regimens.&#xD;
&#xD;
        -  Compare the cumulative systemic corticosteroid exposure in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Compare the incidence and degree of hypothalamic-pituitary-adrenal axis suppression in&#xD;
           patients treated with these regimens who have not experienced treatment failure by study&#xD;
           day 50.&#xD;
&#xD;
        -  Compare the safety of these regimens in these patients.&#xD;
&#xD;
        -  Compare the total deaths and causes of death through 200 days post-transplantation of&#xD;
           patients treated with these regimens.&#xD;
&#xD;
        -  Assess the pharmacokinetic profile of beclomethasone dipropionate in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, parallel, multicenter study.&#xD;
      Patients are stratified according to graft tissue source (2 HLA haplotype-identical sibling&#xD;
      vs all others) and topical steroid use at baseline (yes vs no). Patients are randomized to 1&#xD;
      of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral beclomethasone dipropionate 4 times daily on days 1-50.&#xD;
           Patients also receive oral prednisone (or methylprednisolone IV) twice daily on days&#xD;
           1-10 with a rapid taper on days 11-17 followed by low-dose prednisone on days 18-80.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo 4 times daily on days 1-50. Patients also receive&#xD;
           prednisone (or methylprednisolone) as in arm I.&#xD;
&#xD;
      In both arms, treatment continues in the absence of poorly controlled GVHD at day 10 or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at days 51, 60, and 80 and then at 200 days post-transplantation.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 130 patients (65 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Graft Versus Host Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beclomethasone dipropionate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed graft-vs-host disease (GVHD) with gastrointestinal symptoms&#xD;
&#xD;
               -  Endoscopic evidence of grade II intestinal GVHD without another plausible&#xD;
                  etiology&#xD;
&#xD;
               -  Confirmed by biopsy of colon, stomach, small intestine, esophagus, or skin within&#xD;
                  72 hours prior to study entry&#xD;
&#xD;
          -  At least 10 days post allogeneic hematopoietic stem cell transplantation&#xD;
&#xD;
          -  Received prior anti-candidal prophylaxis of the oropharynx with an effective drug&#xD;
&#xD;
          -  Confirmed absence of intestinal infection within the past 7 days&#xD;
&#xD;
          -  No liver GVHD with bilirubin greater than 3 mg/dL&#xD;
&#xD;
          -  No skin GVHD other than a slowly evolving rash that involves no more than 50% of the&#xD;
             body surface&#xD;
&#xD;
          -  No more than 1,000 mL/day of diarrhea on any 1 day within the past 3 days&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Able to swallow tablets&#xD;
&#xD;
          -  No multi-organ failure&#xD;
&#xD;
          -  No sepsis syndrome&#xD;
&#xD;
          -  No other condition with high mortality&#xD;
&#xD;
          -  No infection of the mouth or esophagus with a fungal organism&#xD;
&#xD;
          -  No persistent vomiting of oral intake&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 30 days since prior biologic agents&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 30 days since prior systemic (oral or parenteral) prescription&#xD;
             corticosteroids administered for prophylaxis or treatment of GVHD or another&#xD;
             inflammatory disease process&#xD;
&#xD;
          -  Concurrent dexamethasone as an antiemetic or to lessen side effects during medication&#xD;
             or blood product administration allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior beclomethasone dipropionate&#xD;
&#xD;
          -  At least 30 days since prior investigational drugs or devices&#xD;
&#xD;
          -  Concurrent immunosuppressants (e.g., cyclosporine, tacrolimus, sirolimus,&#xD;
             methotrexate, or mycophenolate mofetil) allowed for GVHD prophylaxis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel-Angel Perales, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2004</verification_date>
  <study_first_submitted>August 5, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <keyword>graft versus host disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

